Influenza virus polymerase inhibitors in clinical development

Frederick G. Hayden(University of Virginia), Nahoko Shindo(World Health Organization - Pakistan)
Current Opinion in Infectious Diseases
February 6, 2019
10.1097/qco.0000000000000532
Cited by 256

Related Papers

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
COVID-19: what is next for public health?
|The Lancet|2020|1.2k
Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection
|New England Journal of Medicine|2010|1.1k
Middle East Respiratory Syndrome
|New England Journal of Medicine|2017|511
Clinical Presentation of Patients with Ebola Virus Disease in Conakry, Guinea
|New England Journal of Medicine|2014|389